195 related articles for article (PubMed ID: 32961024)
1. Effect of SLCO1B1 Polymorphisms on High-Dose Methotrexate Clearance in Children and Young Adults With Leukemia and Lymphoblastic Lymphoma.
Schulte RR; Choi L; Utreja N; Van Driest SL; Stein CM; Ho RH
Clin Transl Sci; 2021 Jan; 14(1):343-353. PubMed ID: 32961024
[TBL] [Abstract][Full Text] [Related]
2. Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition.
Ramsey LB; Bruun GH; Yang W; Treviño LR; Vattathil S; Scheet P; Cheng C; Rosner GL; Giacomini KM; Fan Y; Sparreboom A; Mikkelsen TS; Corydon TJ; Pui CH; Evans WE; Relling MV
Genome Res; 2012 Jan; 22(1):1-8. PubMed ID: 22147369
[TBL] [Abstract][Full Text] [Related]
3. Genetic factors involved in delayed methotrexate elimination in children with acute lymphoblastic leukemia.
Cheng Y; Chen MH; Zhuang Q; Lin BJ; Chen YY; Yang L; Liu MB; Que WC; Qiu HQ
Pediatr Blood Cancer; 2021 May; 68(5):e28858. PubMed ID: 33501733
[TBL] [Abstract][Full Text] [Related]
4. Impact of SLCO1B1 521T > C variant on leucovorin rescue and risk of relapse in childhood acute lymphoblastic leukemia treated with high-dose methotrexate.
Zhang HN; He XL; Wang C; Wang Y; Chen YJ; Li JX; Niu CH; Gao P
Pediatr Blood Cancer; 2014 Dec; 61(12):2203-7. PubMed ID: 25130190
[TBL] [Abstract][Full Text] [Related]
5. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.
Radtke S; Zolk O; Renner B; Paulides M; Zimmermann M; Möricke A; Stanulla M; Schrappe M; Langer T
Blood; 2013 Jun; 121(26):5145-53. PubMed ID: 23652803
[TBL] [Abstract][Full Text] [Related]
6. Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.
Csordas K; Lautner-Csorba O; Semsei AF; Harnos A; Hegyi M; Erdelyi DJ; Eipel OT; Szalai C; Kovacs GT
Br J Haematol; 2014 Aug; 166(3):410-20. PubMed ID: 24712521
[TBL] [Abstract][Full Text] [Related]
7. [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia].
Zhang H; He X; Li J; Wang Y; Wang C; Chen Y; Niu C; Gao P
Zhonghua Er Ke Za Zhi; 2014 Oct; 52(10):770-6. PubMed ID: 25537545
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacogenetics of high-dose methotrexate in Chinese adult patients with non-Hodgkin lymphoma: a population analysis.
Yang L; Wu H; de Winter BCM; Sheng CC; Qiu HQ; Cheng Y; Chen J; Zhao QL; Huang J; Jiao Z; Xie RX
Cancer Chemother Pharmacol; 2020 May; 85(5):881-897. PubMed ID: 32246190
[TBL] [Abstract][Full Text] [Related]
9. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects.
Treviño LR; Shimasaki N; Yang W; Panetta JC; Cheng C; Pei D; Chan D; Sparreboom A; Giacomini KM; Pui CH; Evans WE; Relling MV
J Clin Oncol; 2009 Dec; 27(35):5972-8. PubMed ID: 19901119
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia.
Lopez-Lopez E; Martin-Guerrero I; Ballesteros J; Piñan MA; Garcia-Miguel P; Navajas A; Garcia-Orad A
Pediatr Blood Cancer; 2011 Oct; 57(4):612-9. PubMed ID: 21387541
[TBL] [Abstract][Full Text] [Related]
11. Delayed Methotrexate Elimination after Administration of a Medium Dose of Methotrexate in a Patient with Genetic Variants Associated with Methotrexate Clearance.
Tatebe Y; Kanamitsu K; Kanzaki H; Ishida H; Fujiwara K; Washio K; Kitamura Y; Sendo T; Shimada A; Tsukahara H
Acta Med Okayama; 2020 Dec; 74(6):545-550. PubMed ID: 33361876
[TBL] [Abstract][Full Text] [Related]
12. Endogenous Metabolites-Mediated Communication Between OAT1/OAT3 and OATP1B1 May Explain the Association Between SLCO1B1 SNPs and Methotrexate Toxicity.
Martinez D; Muhrez K; Woillard JB; Berthelot A; Gyan E; Choquet S; Andrès CR; Marquet P; Barin-Le Guellec C
Clin Pharmacol Ther; 2018 Oct; 104(4):687-698. PubMed ID: 29285751
[TBL] [Abstract][Full Text] [Related]
13. Effects of
Yang FF; Xue TL; Gao C; Wu Y; Lin W; Li J; Zhang RD; Zheng HY; Liu SG
Pharmacogenomics; 2022 Oct; 23(15):821-834. PubMed ID: 36193736
[No Abstract] [Full Text] [Related]
14. Genome-wide study of methotrexate clearance replicates SLCO1B1.
Ramsey LB; Panetta JC; Smith C; Yang W; Fan Y; Winick NJ; Martin PL; Cheng C; Devidas M; Pui CH; Evans WE; Hunger SP; Loh M; Relling MV
Blood; 2013 Feb; 121(6):898-904. PubMed ID: 23233662
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic study of methotrexate in children with acute lymphoblastic leukemia.
Zhang C; Zhai S; Yang L; Wu H; Zhang J; Ke X
Int J Clin Pharmacol Ther; 2010 Jan; 48(1):11-21. PubMed ID: 20040335
[TBL] [Abstract][Full Text] [Related]
16. Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy.
Yanagimachi M; Goto H; Kaneko T; Naruto T; Sasaki K; Takeuchi M; Tanoshima R; Kato H; Yokosuka T; Kajiwara R; Fujii H; Tanaka F; Goto S; Takahashi H; Mori M; Kai S; Yokota S
Int J Hematol; 2013 Dec; 98(6):702-7. PubMed ID: 24241962
[TBL] [Abstract][Full Text] [Related]
17. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma.
Faganel Kotnik B; Grabnar I; Bohanec Grabar P; Dolžan V; Jazbec J
Eur J Clin Pharmacol; 2011 Oct; 67(10):993-1006. PubMed ID: 21509569
[TBL] [Abstract][Full Text] [Related]
18. [Investigation on individualized adjustment of target range of high-dose methotrexate].
Hua Y; Zhao WH; Lu XT; Yang LH; Lu W
Zhonghua Er Ke Za Zhi; 2008 Mar; 46(3):203-8. PubMed ID: 19099710
[TBL] [Abstract][Full Text] [Related]
19. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
[TBL] [Abstract][Full Text] [Related]
20. High-dose methotrexate in Egyptian pediatric acute lymphoblastic leukemia: the impact of ABCG2 C421A genetic polymorphism on plasma levels, what is next?
El Mesallamy HO; Rashed WM; Hamdy NM; Hamdy N
J Cancer Res Clin Oncol; 2014 Aug; 140(8):1359-65. PubMed ID: 24718721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]